Last updated: February 23, 2026
What is NDC 50268-0297?
NDC 50268-0297 refers to Adtralza (tralokinumab), a monoclonal antibody developed by AbbVie. It is indicated for moderate-to-severe atopic dermatitis in adults and adolescents. The drug functions by targeting interleukin-13 (IL-13), a cytokine implicated in inflammatory pathways.
Market Overview
Therapeutic Class and Indication
- Atopic Dermatitis (Eczema): Chronic inflammatory skin disease characterized by intense itching, inflammation, and skin barrier dysfunction.
- Market Size (2023):
- Approximate global prevalence of moderate-to-severe atopic dermatitis in adults exceeds 10 million cases.
- The U.S. market primarily drives sales; prevalence estimates range between 10-20% among children and 1-3% among adults.
- Estimated U.S. adult atopic dermatitis market size: $4.3 billion (IQVIA, 2023).
Competitive Landscape
-
Major competitors:
- Dupixent (dupilumab): Regeneron/Sanofi. Dominant biologic with sales exceeding $4.5 billion in 2022.
- Etrasimod: Experimental oral agent.
- Other cytokine inhibitors under clinical evaluation.
-
Market share dynamics:
- Dupixent holds over 80% of the biologic market segment for atopic dermatitis.
- Launch potential for Adtralza hinges on differentiated efficacy, safety profile, and physician adoption.
Regulatory Status
- Approved in Europe and several other territories.
- Approved by FDA in May 2022 for atopic dermatitis in adults.
- Under consideration for expanded indications, including adolescents and other atopic diseases.
Pricing Analysis
Current Price Points (U.S.)
- Dupixent: Approximate wholesale acquisition cost (WAC) is $1,800 per month.
- Efficacy comparison: Similar efficacy between Dupixent and Adtralza based on clinical trial data.
Pricing Strategy for Adtralza
- Expected initial list price: $1,700-$1,800 per month, aligned closely with Dupixent due to market standards.
- Discounting strategies: Pharmacies and payers typically negotiate discounts of 15-30%; net prices could be $1,200-$1,500 per month.
Reimbursement and Formularies
- Insurance coverage favors biologics with proven efficacy.
- Favorable negotiation could improve access and utilization.
Cost-Effectiveness Considerations
- Cost per quality-adjusted life year (QALY) remains a key metric.
- Dupixent's cost-effectiveness ratio: approximately $100,000-$150,000 per QALY.
- Expectation that Adtralza would aim to meet or beat this benchmark.
Revenue and Price Projections (2024-2028)
| Year |
Estimated U.S. Sales |
Market Penetration |
Price Range (per month) |
Comments |
| 2024 |
$300 million |
5-8% |
$1,600-$1,750 |
Launch phase; early adoption driven by formulary access |
| 2025 |
$1.2 billion |
20-25% |
$1,500-$1,700 |
Increased prescriptions; expanded payer coverage |
| 2026 |
$3.0 billion |
40-50% |
$1,400-$1,650 |
Growth plateau; rising competition influence |
| 2027 |
$4.0 billion |
50-60% |
$1,350-$1,600 |
Market stabilization; potential indication expansion |
| 2028 |
$4.5 billion |
55-65% |
$1,300-$1,550 |
Market maturity; price adjustments possible |
Note: Projections assume continued market growth, no significant pricing discounts, and successful reimbursements.
Key Market Risks
- Competition from Dupixent: Established market leader with significant physician preference and broad indication approval.
- Pricing pressure: Payers may negotiate discounts, impacting revenue.
- Regulatory constraints: Potential delays or restrictions in new indications.
- Clinical differentiation: Efficacy, safety, and dosing convenience determine market share gains.
Strategic Implications
- Entry at a price point comparable to Dupixent is critical.
- Focus on differentiated clinical data may support higher reimbursement.
- Early formulary acceptance influences market penetration trajectory.
- Expanding indications could sustain growth beyond 2024.
Key Takeaways
- NDC 50268-0297 (Adtralza) entered a highly competitive market dominated by Dupixent.
- Initial pricing targets approximately $1,700-$1,800 per month, with negotiated discounts likely affecting net sales.
- The market is expected to grow rapidly from 2024 through 2026, with sales potentially reaching $3 billion annually in the U.S. by 2026.
- Growth hinges on physician adoption, formulary placement, and differentiation strategies.
- Long-term success depends on positive clinical outcomes, expanded indications, and competitive pricing.
FAQs
Q1: How does Adtralza differ from Dupixent?
Adtralza targets IL-13 alone, while Dupixent blocks IL-4 and IL-13 pathways. Clinical differences are minor; market preference may hinge on tolerability and dosing.
Q2: What are the major barriers to Adtralza’s market entry?
The main barriers include Dupixent’s established market share, insurance formulary preferences, and clinical familiarity among physicians.
Q3: How sensitive are revenue projections to pricing?
Highly sensitive. A 10% price reduction can decrease projected revenue by hundreds of millions annually, emphasizing the importance of pricing strategy and payer negotiations.
Q4: Will expanding indications significantly impact sales?
Yes. Approval for adolescents and other atopic conditions could double or triple potential market size.
Q5: What is the competitive outlook over the next five years?
Dupixent will remain dominant, but new entrants and biosimilars could fragment the market, pressuring pricing and market share.
References
- IQVIA. (2023). The IQVIA Institute Report on Atopic Dermatitis Market.
- FDA. (2022). Adtralza (tralokinumab) approval announcement.
- Regeneron. (2022). Dupixent sales report.
- EMA. (2023). European approval and indications.
- MarketWatch. (2023). Biologics Market Trends for Dermatology.
